secwatch.observer — SEC 8-K summary
======================================

Issuer:     Orchestra BioMed Holdings, Inc. (OBIO)
CIK:        0001814114
Form:       8-K
Filed at:   2025-07-31T23:59:59+00:00
Accession:  0001104659-25-072678
Event type: other_material
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 2.03, 3.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Orchestra BioMed secures up to $67M in financing from Ligand & Medtronic; cash ~$33.9M
--------------------------------------------------------------------------------

- Ligand pays $35M for tiered revenue rights on BACKBEAT & Virtue SAB products; also buys $5M stock and gets 2M-share warrant.
- Medtronic provides $20M convertible loan at 11% interest, plus up to $12M equity purchase in subsequent offering.
- Hercules loan amended: amortization delayed, borrowing capacity increased by $15M; warrant terms modified.
- Preliminary June 30 cash $33.9M; Terumo mediation expected to complete in Q3 2025.
- BACKBEAT study enrollment now expected mid-2026; FDA-approved amendments to expand patient eligibility.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1814114/000110465925072678/0001104659-25-072678-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1814114/000110465925072678/tm2522158d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-072678

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer